The 2019 congressional hearing season kicked off with dueling drug pricing hearings in the House and Senate that provided plenty of drama and tweetable moments – as well as repeated bipartisan promises that future hearings will shine a much harsher light on pharmaceutical company executives than what they have faced the past.
Unlike in recent years, mainstream pharmaceutical companies (and not just “bad actors” like Valeant and Turing) are now clearly in...







